Eleven therapeutic agents had estimated IC50 values that indicated increased sensitivity for the high‐risk group, including AKT inhibitor and Embelin for ESCC (Figure 9A), and AS601245, AZD6482, BMS.536924, LFM.A13, NVP.TAE684, PF.02341066, Roscovitine, SB.216763 and XMD8.85 for EAC (Figure 9B). Here, AKT1 is linked to esophageal squamous cell carcinoma.